Korro Bio (NASDAQ:KRRO) Major Shareholder Rick Yang Acquires 207,100 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Rick Yang purchased 207,100 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Korro Bio Stock Up 13.0%

KRRO traded up $1.49 during trading on Friday, reaching $12.99. 502,826 shares of the company were exchanged, compared to its average volume of 235,937. Korro Bio, Inc. has a 12-month low of $5.20 and a 12-month high of $55.89. The company’s 50-day moving average is $10.90 and its two-hundred day moving average is $20.23. The company has a market cap of $122.38 million, a price-to-earnings ratio of -1.38 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($5.32) earnings per share for the quarter, missing the consensus estimate of ($1.93) by ($3.39). Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $0.43 million. Equities analysts forecast that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Korro Bio in the 3rd quarter worth about $39,000. Wells Fargo & Company MN lifted its stake in shares of Korro Bio by 45.5% in the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after purchasing an additional 2,352 shares during the period. Guggenheim Capital LLC bought a new stake in shares of Korro Bio during the fourth quarter valued at approximately $84,000. Jain Global LLC purchased a new stake in Korro Bio in the fourth quarter worth $85,000. Finally, Deutsche Bank AG raised its holdings in Korro Bio by 241.9% in the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock worth $102,000 after purchasing an additional 9,027 shares in the last quarter. 13.18% of the stock is currently owned by institutional investors.

Trending Headlines about Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target (~74% upside vs. the recent share level), which can attract momentum buyers and institutional interest. Raymond James Upgrade
• Positive Sentiment: Multiple large shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed purchases of ~207,100 shares each at about $11.11 (~$2.3M per filing), increasing their stakes — a strong insider/major‑holder vote of confidence that can support the stock. Insider / Major Holder Buys
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for potential treatment of hyperammonemia, is advancing a GalNAc candidate for alpha‑1 antitrypsin deficiency (on track for a development candidate nomination in Q2 2026), and completed an oversubscribed $85M private placement — management says cash runway now extends into H2 2028, reducing near‑term financing risk. Corporate Update & Cash Raise
• Neutral Sentiment: Revenue modestly beat expectations ($1.29M vs. ~$0.42M est.), showing some commercial or other revenue pickup, but the dollar amounts are small relative to R&D burn — limited immediate impact on profitability. Earnings Press Release
• Negative Sentiment: Large quarterly loss: KRRO reported a Q4 EPS loss of ($5.32) vs. consensus (~($1.93)), driving very negative margins and return‑on‑equity metrics — a reminder of high execution risk and binary clinical development outcomes that can trigger volatility. Q4 Results & EPS Miss

Wall Street Analysts Forecast Growth

KRRO has been the topic of a number of research analyst reports. JonesTrading lowered shares of Korro Bio from a “buy” rating to a “hold” rating in a report on Friday, November 14th. Clear Str raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a report on Friday, January 9th. Wall Street Zen downgraded Korro Bio from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Finally, Piper Sandler downgraded shares of Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 target price on the stock. in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $44.50.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.